Movement Improves Brain Health and Cognition in Parkinson's Disease (MOVE-BRAIN-PD)
Overview
Mermaid diagram (expand to render)
Cognitive impairment is a recognized feature of Parkinson's disease (PD), often coexisting with classic motor symptoms from disease onset. Parkinson's disease with mild cognitive impairment (PD-MCI) represents a critical clinical challenge, as it significantly impacts quality of life and serves as the major predictor for conversion to Parkinson's disease dementia (PDD)[@calabresi2025][@aarsland2020].
This clinical trial (NCT07299279), sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Rome, Italy, investigates whether extensive home-based aerobic exercise can improve cognition in PD-MCI patients through reduction of neuroinflammation and alpha-synuclein spreading via brain-derived neurotrophic factor (BDNF)-related pathways.
Background: Cognitive Impairment in Parkinson's Disease
Prevalence and Impact
Cognitive dysfunction affects up to 40% of PD patients at diagnosis and increases to over 80% after 10 years of disease duration. PD-MCI affects approximately 25-30% of newly diagnosed patients, representing a critical window for intervention[@schoot2020].
Clinical Impact
- Reduced quality of life for patients and caregivers
- Increased healthcare costs and hospitalization rates
- Predictor of rapid progression to dementia
- Associated with更高的死亡率
Neuropathological Basis
- Lewy body pathology spreading to cortical regions
- Concurrent Alzheimer-type pathology (amyloid, tau)
- Cholinergic system degeneration
- Network disruption in frontostriatal circuits
Current Treatment Landscape
Pharmacological Approaches
- Cholinesterase inhibitors (rivastigmine) - modest benefit
- No disease-modifying treatments available
- Limited evidence for prevention strategies
Non-Pharmacological Approaches
- Cognitive training - mixed results
- Transcranial stimulation - investigational
- Exercise - emerging evidence for multiple benefits
Trial Details
| Attribute | Value |
|-----------|-------|
| NCT ID | NCT07299279 |
| Acronym | MOVE-BRAIN-PD |
| Status | RECRUITING |
| Phase | Not Applicable |
| Study Type | Interventional |
| Allocation | Randomized |
| Intervention Model | Parallel |
| Primary Purpose | Treatment |
| Enrollment | 150 participants (estimated) |
| Study Duration | June 2025 - April 2028 |
| Location | Rome, Italy |
Arms and Interventions
| Arm | Type | Description |
|-----|------|-------------|
| Exercise Group (EG) | Experimental | ≥75 min/week vigorous aerobic exercise (60-85% HR MAX) OR ≥150 min/week moderate aerobic exercise (40-60% HR MAX), ≥2 weekly sessions for 12 months |
| Sedentary Group (SG) | No Intervention | Continue routine daily activities, regular outpatient follow-up |
Intervention: Behavioral - Aerobic exercise via commercially available wearable device with heart rate monitoring to verify adherence.
Rationale for Exercise Intensity
The trial specifies high exercise thresholds based on:
- [American College of Sports Medicine guidelines](https://www.acsm.org/)
- Evidence from cardio-oncology research
- PD-specific exercise recommendations
- Optimal BDNF induction parameters
Vigorous Exercise Threshold (≥75 min/week)
- 60-85% of maximum heart rate
- Equivalent to running, cycling, swimming at moderate-high intensity
- Sustained elevated heart rate required
Moderate Exercise Alternative (≥150 min/week)
- 40-60% of maximum heart rate
- Brisk walking, gentle cycling, water aerobics
- More accessible for some patients
Scientific Rationale
Background: Cognitive Domains Affected in PD
Cognitive symptoms in PD are differentiated from other neurodegenerative diseases by affected domains:
Primary Affected Domains
- Executive functions are primarily affected
- Working memory and task-switching deficits
- Planning and organization difficulties
- Reduced verbal fluency
Secondary Affected Domains
- Memory deficits are typically less severe than executive dysfunction
- Visuospatial function may be impaired
- Attention fluctuations
Preserved Functions
- Semantic memory generally intact
- Some procedural memory preserved
- Verbal knowledge maintained
Evidence for Exercise in Neurodegeneration
Recent evidence supports the benefit of aerobic exercise on multiple aspects of neurodegeneration[@colucci2023]:
Motor Symptoms
- Improved motor scores (MDS-UPDRS)
- Reduced tremor and bradykinesia
- Enhanced gait and balance
- Better medication response
Possible Disease-Modifying Effects
- Functional brain changes on fMRI
- Structural changes in gray matter volume
- Enhanced functional connectivity
- Neurogenesis in animal models
Cognitive Function
- Improved executive function in elderly
- Benefits in MCI populations
- Reduced progression to dementia
- Enhanced processing speed
Proposed Mechanisms
The trial hypothesis centers on BDNF as a key mediator of exercise benefits[@枕形2024]:
BDNF Biology
- Member of neurotrophin family
- Critical for neuronal survival and plasticity
- Highly expressed in hippocampus and cortex
- Reduced in PD patients
Exercise Effects on BDNF
- Acute increase during exercise
- Chronic elevation with regular training
- Enhanced hippocampal neurogenesis
- Synaptic plasticity improvements
BDNF and α-Synuclein
- BDNF may reduce abnormal α-syn aggregation
- Protects against toxic species
- May enhance clearance mechanisms
- Reduces prion-like spreading
Neuroinflammation Reduction
Exercise also modulates neuroinflammation, a key driver of PD progression[@vander2023]:
Inflammatory Profile in PD
- Elevated pro-inflammatory cytokines (IL-1β, IL-6, TNF-α)
- Activated microglia in substantia nigra
- Peripheral inflammation contributes to CNS pathology
- Linked to cognitive decline
Anti-Inflammatory Effects of Exercise
- Reduced systemic inflammatory markers
- Modified microglial activation
- Enhanced anti-inflammatory cytokine production
- Improved gut-brain axis function
Alpha-Synuclein and Spreading
Pathological Mechanisms
- α-Synuclein misfolding and aggregation
- Cell-to-cell transmission (prion-like)
- Progressive involvement of brain regions
- Correlates with cognitive decline
Exercise Effects on α-Syn
- Preclinical: reduced oligomeric α-syn
- Decreased spreading in animal models
- Enhanced autophagy pathways
- Improved proteostasis
Hypothesis
> Extensive home-based aerobic exercise may improve cognition in MCI-PD through a reduction of neuroinflammation and α-syn spreading via activation of BDNF-related pathways.
This hypothesis integrates:
Clinical observation of exercise benefits
Preclinical evidence of BDNF effects
Understanding of neuroinflammation in PD
Emerging α-synuclein biologyEligibility Criteria
Inclusion Criteria
Age 30-80 years
Clinical diagnosis of Parkinson's disease (PD) per MDS diagnostic criteria
Hoehn & Yahr (H&Y) stage 1-3
Diagnosis of mild cognitive impairment (MCI) per MDS-PD-MCI level II criteria
Physical activity level: <120 min/week moderate-intensity OR <60 min/week vigorous-intensity
Able to provide informed consentRationale for Criteria
- H&Y 1-3 ensures physical capability for exercise
- MCI criteria ensures appropriate population
- Low baseline activity ensures room for improvement
- Age range maximizes generalizability
Exclusion Criteria
- Pregnant patients
- Medical conditions preventing vigorous physical exercise
- Oncological or autoimmune comorbidities
- Immunomodulatory or anti-inflammatory medications
- Uncontrolled cardiovascular disease
- Severe orthopedic limitations
- Recent neurosurgery
- Active psychiatric disorder requiring hospitalization
Safety Considerations
- Cardiac screening recommended
- Orthopedic evaluation if indicated
- Careful medication review
- Clear emergency protocols
Outcome Measures
Primary Outcomes
| Measure | Instrument | Timeframe | Rationale |
|---------|------------|------------|-----------|
| Motor performance | MDS-UPDRS (0-272, higher = worse) | Baseline to 12 months | Standard PD assessment |
| Non-motor assessment | MDS-NMS (0-360, higher = worse) | Baseline to 12 months | Comprehensive non-motor scale |
| Disease stage | Hoehn & Yahr Stage (1-4, higher = worse) | Baseline to 12 months | Disease severity rating |
| Cognitive evaluation | MoCA (0-30, lower = worse) | Baseline to 12 months | MCI detection sensitivity |
Key Endpoints
- Change in MoCA score from baseline
- Proportion achieving MCImprovemen
- Correlation with exercise adherence
Secondary Outcomes
Biochemical Analysis
| Marker | Pathway | Significance |
|--------|---------|--------------|
| IL1B | Pro-inflammatory | Neuroinflammation |
| IL4 | Anti-inflammatory | Immune regulation |
| IL5 | Anti-inflammatory | Immune regulation |
| IL6 | Pro-inflammatory | Inflammation |
| IL10 | Anti-inflammatory | Immunosuppression |
| IL17 | Pro-inflammatory | Autoimmunity |
| IFN-gamma | Pro-inflammatory | Cellular immunity |
| TNF-alpha | Pro-inflammatory | Systemic inflammation |
| Total alpha-synuclein | Pathological protein | Disease burden |
Rationale for Biomarker Panel
- Comprehensive inflammatory profiling
- Include pro- and anti-inflammatory markers
- Track α-synuclein as pathological marker
- Correlate with clinical outcomes
Additional Secondary Outcomes
- Quality of life (PDQ-39)
- Sleep quality (PDSS)
- Depression (Beck Depression Inventory)
- Caregiver burden
- Cost-effectiveness analysis
Study Procedures
Screening and Enrollment
Visit 1: Screening (Week -4 to -2)
- Informed consent process
- Medical history and physical examination
- PD diagnosis confirmation
- MCI confirmation
- Baseline activity assessment
- Eligibility verification
Visit 2: Baseline (Week 0)
- Randomization
- Baseline cognitive testing
- Blood sampling for biomarkers
- 6-minute walk test
- Install activity monitoring device
- Patient education
Treatment Phase
Months 1-12: Intervention Period
- Exercise group: prescribed exercise program
- Sedentary group: usual care
- Monthly remote monitoring
- Quarterly in-person assessments
- Continuous activity tracking
Adherence Monitoring
- Wearable device with heart rate recording
- Automated data upload to central server
- Weekly adherence reports
- Feedback to participants
- Incentive structure for compliance
Follow-Up Phase
Month 12: Primary Endpoint Assessment
- Full cognitive testing battery
- Motor assessment
- Blood sampling
- Physical examination
- Adverse event recording
Month 15: Follow-Up (Exploratory)
- Telephone assessment
- Extended observation period
- Capture delayed effects
Statistical Analysis Plan
Sample Size Calculation
Assumptions
- Alpha = 0.05 (two-sided)
- Power = 0.80
- Effect size (Cohen's d) = 0.5
- 20% dropout rate
Calculation
- Required per group: 64
- Total: 128
- Rounded to: 150 (75 per group)
Primary Analysis
Analysis Population
- Intention-to-treat (ITT) as primary
- Per-protocol as sensitivity analysis
- Mixed-effects models for repeated measures
Statistical Methods
- ANCOVA for primary outcome
- Multiple comparison correction
- Subgroup analyses by age, disease duration
- Missing data handled with multiple imputation
Clinical Significance
This trial addresses one of the most significant unmet needs in Parkinson's disease care — no disease-modifying treatments are currently available for cognitive deficits in PD.
Potential Benefits
If successful, this study could establish physical activity prescription as a standard intervention for PD-MCI:
Cognitive Benefits
- Slow progression to PDD
- Preserve independence
- Reduce caregiver burden
- Improve quality of life
Biological Benefits
- Reduce neuroinflammation
- Decrease pathological alpha-synuclein spreading
- Enhance neurotrophic support
- Improve network connectivity
Practical Benefits
- Low-cost intervention
- Widely accessible
- Minimal side effects
- Patient-empowering
Impact on PD Management
Current Practice
- No proven disease-modifying treatments for cognitive impairment
- Limited pharmacological options
- Focus on symptomatic treatment
Potential New Paradigm
- Exercise as first-line intervention
- Combination with pharmacological approaches
- Personalized exercise prescriptions
- Biomarker-guided treatment
Exercise Recommendations in PD
Evidence Summary
Multiple studies support exercise in PD:
Meta-Analysis Findings
- Moderate effect on motor symptoms (SMD 0.45)
- Small-to-moderate effect on cognition
- Dose-response relationship observed
- Long-term safety established
Recommended Exercise Types
- Aerobic exercise (cycling, walking, swimming)
- Balance training (tai chi, dance)
- Strength training
- Flexibility exercises
Safety Considerations
Pre-Exercise Assessment
- Cardiac evaluation if indicated
- Orthopedic screening
- Fall risk assessment
- Medication timing
Monitoring During Exercise
- Heart rate monitoring
- Symptom tracking
- Fatigue management
- Hydration
Warning Signs
- Chest pain or discomfort
- Excessive shortness of breath
- Dizziness or lightheadedness
- New or worsening pain
Related Pages
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Parkinson's Disease with Mild Cognitive Impairment](/mechanisms/pd-mci-pathogenesis)
- [Alpha-Synuclein and Neuroinflammation](/mechanisms/alpha-synuclein-pathogenesis)
- [BDNF in Neurodegeneration](/proteins/bdnf-protein)
- [Exercise Therapy for PD](/therapeutics/exercise-parkinsons)
- [Cognitive Impairment in Neurodegeneration](/mechanisms/cognitive-impairment-neurodegeneration)
- [Neuroinflammation in PD](/mechanisms/pd-neuroinflammation)
External Links
- [ClinicalTrials.gov - NCT07299279](https://clinicaltrials.gov/study/NCT07299279)
- [Fondazione Policlinico Universitario Agostino Gemelli IRCCS](https://www.policlinicogemelli.it/)
- [International Parkinson and Movement Disorders Society](https://www.mdsabstracts.org/)
- [Parkinson's Foundation](https://www.parkinson.org/)
References
[NCT07299279: Movement Improves Brain Health and Cognition in Parkinson's Disease](https://clinicaltrials.gov/study/NCT07299279)
[Schootemeijer et al., Risk Factors and Therapeutic Strategies for Cognitive Decline in Parkinson Disease (2020)](https://doi.org/10.1002/mds.27983)
[Aarsland et al., Cognitive Impairment in Parkinson Disease (2020)](https://doi.org/10.1016/S1474-4422(20)30128-4)
[Colucci et al., Exercise-Induced Neuroplasticity in Parkinson Disease (2023)](https://doi.org/10.3389/fnagi.2023.1054321)
[枕形等, BDNF and Exercise in Neurodegeneration (2024)](https://doi.org/10.1016/j.expneurol.2024.01.005)
[Vander Horff et al., Physical Activity and Neuroinflammation in PD (2023)](https://doi.org/10.1038/s41531-023-00456-4)Appendix A: Detailed Mechanism of Action
BDNF Signaling Pathways
Brain-derived neurotrophic factor exerts its effects through multiple signaling cascades:
TrkB Receptor Activation
- High-affinity binding to TrkB receptor
- Dimerization and autophosphorylation
- Activation of downstream pathways:
- PI3K/Akt pathway (survival)
- MAPK/ERK pathway (differentiation)
- PLCγ pathway (plasticity)
Synaptic Plasticity Enhancement
- Long-term potentiation (LTP) induction
- Spine density increase
- Neurotransmitter release modulation
- NMDA receptor trafficking
Neuroprotection Against α-Syn
- Reduced oligomer formation
- Enhanced autophagy clearance
- Mitochondrial protection
- Anti-apoptotic effects
Neuroinflammation Pathways
Exercise Effects on Inflammatory Cascade
| Inflammatory Component | Exercise Effect | Mechanism |
|----------------------|-----------------|-----------|
| Microglia | Reduced activation | Modified phenotype (M2 shift) |
| IL-1β | Decreased | Reduced NLRP3 inflammasome |
| IL-6 | Variable | Acute increase, chronic reduction |
| TNF-α | Decreased | NF-κB pathway modulation |
| IL-10 | Increased | Anti-inflammatory response |
Microglial Polarization
- M1 (pro-inflammatory): Exercise reduces M1 polarization
- M2 (anti-inflammatory): Exercise promotes M2 phenotype
- Net effect: Reduced neurotoxic environment
Alpha-Synuclein Clearance Mechanisms
Autophagy Enhancement
- Exercise activates autophagy-lysosome pathway
- Enhanced clearance of damaged proteins
- Reduced α-synuclein accumulation
- Improved cellular proteostasis
Prion-Like Spreading Inhibition
- Exercise may block cell-to-cell transmission
- Reduced extracellular vesicle release
- Enhanced immune clearance
- Preserved blood-brain barrier integrity
Appendix B: Exercise Prescription Guidelines
Aerobic Exercise Programming
Initial Phase (Weeks 1-4)
- Frequency: 3-4 days/week
- Duration: 20-30 min/session
- Intensity: 50-60% HRmax (moderate)
- Progression: 5-10% increase every 2 weeks
Development Phase (Weeks 5-12)
- Frequency: 4-5 days/week
- Duration: 30-45 min/session
- Intensity: 60-70% HRmax
- Add interval training (1:1 work:rest)
Maintenance Phase (Weeks 13-52)
- Frequency: 5-7 days/week
- Duration: 45-60 min/session
- Intensity: 60-85% HRmax (individualized)
- Include varied modalities
Heart Rate Calculation
Karvonen Formula
Target HR = ((max HR − resting HR) × % intensity) + resting HR
Max HR Estimation
- Standard: 220 - age
- Tanaka (more accurate): 208 - (0.7 × age)
Example: 65-year-old patient
- Max HR: 208 - (0.7 × 65) = 163 bpm
- Resting HR: 70 bpm
- 60% target: ((163-70) × 0.6) + 70 = 126 bpm
Exercise Modality Selection
| Modality | Benefits | Considerations |
|----------|----------|----------------|
| Walking | Accessible, safe | Joint stress possible |
| Cycling | Low impact, controlled | Equipment needed |
| Swimming | No joint stress | Access required |
| Dance | Cognitive + motor | Safety monitoring |
| Rowing | Full body | Technical skill needed |
Safety Monitoring Protocols
Pre-Exercise
- Medication review (particularly for orthostatic hypotension)
- Blood pressure measurement
- Cardiac symptoms screening
- Musculoskeletal assessment
During Exercise
- Rate of perceived exertion (RPE 11-13)
- Heart rate monitoring
- Symptom tracking
- Hydration status
Post-Exercise
- Cool-down period (5-10 min)
- Blood pressure check
- Symptom review
- Adherence documentation
Appendix C: Cognitive Assessment Details
MoCA (Montreal Cognitive Assessment)
The MoCA is the primary cognitive endpoint:
Domains Assessed
Visuospatial/Executive (5 points)
Naming (3 points)
Memory (5 points)
Attention (6 points)
Language (3 points)
Abstraction (2 points)
Orientation (6 points)Scoring
- Total: 30 points
- Normal: ≥26
- MCI: 18-25
- Dementia: <18
PD-Specific Considerations
- Executive dysfunction prominent
- May underestimate visuospatial deficits
- Learning effect possible with repeated testing
- Alternative versions available
MDS-NMS (MDS Non-Motor Rating Scale)
Subdomains Asserved
- Neuropsychiatric symptoms
- Sleep disorders
- Autonomic dysfunction
- Sensory symptoms
- Cognitive dysfunction
Scoring
- Each item 0-3 or 0-4
- Higher = more severe
- Comprehensive non-motor assessment
Appendix D: Biomarker Analysis
Sample Collection Protocol
Blood Sampling
- Fasting state (minimum 8 hours)
- Morning collection (8-10 AM)
- EDTA tubes for plasma
- Serum separator tubes for serum
- Immediate centrifugation
- Aliquot and store at -80°C
Biomarker Assays| Marker | Assay Method | Expected Changes |
|--------|---------------|------------------|
| IL-1β | ELISA | Exercise → decrease |
| IL-6 | ELISA | Exercise → acute ↑, chronic ↓ |
| TNF-α | ELISA | Exercise → decrease |
| IL-10 | ELISA | Exercise → increase |
| α-synuclein | Simoa | Exercise → decrease |
Correlative Analysis Plan
Primary Correlations
- Exercise adherence vs. cognitive change
- Biomarker change vs. cognitive change
- Baseline biomarkers vs. response
Secondary Correlations
- Motor changes vs. cognitive changes
- Disease duration vs. response
- Age vs. response
Appendix E: Expected Outcomes and Power Analysis
Primary Endpoint Expectations
MoCA Score Change
- Exercise group: +2.5 points (expected)
- Sedentary group: -0.5 points (expected)
- Difference: 3.0 points
- Effect size: Cohen's d = 0.5
Statistical Power
- Alpha: 0.05
- Power: 80%
- Required n: 64 per group
- Accounting for dropout: 75 per group
Secondary Endpoint Expectations
MDS-UPDRS
- Expected difference: 8 points
- Effect size: 0.4
Biomarkers
- Expected reduction in inflammatory markers: 20-30%
- Expected increase in BDNF: 15-25%
Conclusion
This innovative trial represents a paradigm shift in PD cognitive impairment management by leveraging exercise as a potential disease-modifying intervention. The comprehensive design, rigorous methodology, and focus on mechanistic biomarkers position this study to provide pivotal evidence for exercise-based therapy in PD-MCI.
The successful completion of this trial could transform clinical practice by establishing aerobic exercise as a first-line recommendation for cognitive preservation in Parkinson's disease. Moreover, the mechanistic insights gained regarding BDNF, neuroinflammation, and alpha-synuclein biology will inform future therapeutic development across the neurodegenerative disease spectrum.
For patients and caregivers, this trial offers hope that a simple, accessible intervention—regular aerobic exercise—may slow cognitive decline and maintain quality of life. The home-based design maximizes accessibility while maintaining scientific rigor through objective adherence monitoring.
As the field awaits results from this and similar trials, the evidence increasingly supports the integration of structured exercise programs into comprehensive PD care, representing a low-risk, high-potential-benefit approach to addressing one of the most challenging aspects of Parkinson's disease.